(IEX) IDEX - Overview
Sector: Industrials | Industry: Specialty Industrial Machinery | Exchange: NYSE (USA) | Market Cap: 15.184m USD | Total Return: 15.2% in 12m
Avg Turnover: 133M
EPS Trend: -50.9%
Qual. Beats: 5
Rev. Trend: 67.3%
Qual. Beats: 3
Warnings
Below Avwap Earnings
Tailwinds
Confidence
IDEX Corporation (NYSE: IEX) is a diversified global manufacturer specializing in applied solutions and fluidic systems. The company operates through three primary segments: Health & Science Technologies (HST), Fluid & Metering Technologies (FMT), and Fire & Safety/Diversified Products (FSDP). Its product portfolio includes precision pumps, flow meters, rescue tools, and photonic solutions used in medical, industrial, and municipal applications.
The company operates within the industrial machinery sector, utilizing a decentralized business model where individual business units maintain operational autonomy to serve niche markets. This structure allows IDEX to maintain high margins by focusing on highly engineered, mission-critical components that often represent a small fraction of a customers total cost but are essential for system performance. Further insights into these operational efficiencies are available on ValueRay.
Headquartered in Northbrook, Illinois, and incorporated in 1987, IDEX maintains a broad geographic footprint across North America, Europe, and Asia. Its HST segment specifically targets high-growth areas such as life sciences and semiconductor manufacturing, while the FMT and FSDP segments provide stable cash flows through infrastructure and emergency service end-markets.
- Life sciences instrument demand recovery accelerates revenue growth in HST segment
- Municipal infrastructure spending levels dictate volume for fluid and metering solutions
- Raw material cost volatility and supply chain efficiency impact operating margins
- Global industrial production cycles influence capital equipment orders across all segments
- Strategic acquisition integration and synergy realization drive long-term earnings per share growth
| Net Income: 507.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.63 > 1.0 |
| NWC/Revenue: 34.30% < 20% (prev 31.78%; Δ 2.52% < -1%) |
| CFO/TA 0.10 > 3% & CFO 678.4m > Net Income 507.7m |
| Net Debt (1.31b) to EBITDA (939.1m): 1.40 < 3 |
| Current Ratio: 3.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.4m) vs 12m ago -1.85% < -2% |
| Gross Margin: 44.42% > 18% (prev 0.43%; Δ 4.40k% > 0.5%) |
| Asset Turnover: 51.48% > 50% (prev 48.31%; Δ 3.17% > 0%) |
| Interest Coverage Ratio: 11.33 > 6 (EBITDA TTM 939.1m / Interest Expense TTM 64.3m) |
| A: 0.17 (Total Current Assets 1.72b - Total Current Liabilities 506.0m) / Total Assets 6.92b |
| B: 0.67 (Retained Earnings 4.62b / Total Assets 6.92b) |
| C: 0.11 (EBIT TTM 728.8m / Avg Total Assets 6.86b) |
| D: 1.61 (Book Value of Equity 4.63b / Total Liabilities 2.87b) |
| Altman-Z'' = 5.73 = AAA |
| DSRI: 1.07 (Receivables 553.0m/482.6m, Revenue 3.53b/3.28b) |
| GMI: 0.98 (GM 44.42% / 43.40%) |
| AQI: 0.99 (AQ_t 0.69 / AQ_t-1 0.69) |
| SGI: 1.08 (Revenue 3.53b / 3.28b) |
| TATA: -0.02 (NI 507.7m - CFO 678.4m) / TA 6.92b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of May 25, 2026, the stock is trading at USD 205.61 with a total of 535,242 shares traded.
Over the past week, the price has changed by +0.52%,
over one month by +1.97%,
over three months by +0.16% and
over the past year by +15.15%.
IDEX has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy IEX.
- StrongBuy: 6
- Buy: 3
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 237.7 | 15.6% |
P/E Forward = 25.7069
P/S = 4.3013
P/B = 3.9645
P/EG = 1.8557
Revenue TTM = 3.53b USD
EBIT TTM = 728.8m USD
EBITDA TTM = 939.1m USD
Long Term Debt = 1.87b USD (from longTermDebt, last quarter)
Short Term Debt = 500k USD (from shortTermDebt, last quarter)
Debt = 1.90b USD (from shortLongTermDebtTotal, last quarter) + Leases 27.0m
Net Debt = 1.31b USD (calculated: Debt 1.90b - CCE 586.2m)
Enterprise Value = 16.5b USD (15.2b + Debt 1.90b - CCE 586.2m)
Interest Coverage Ratio = 11.33 (Ebit TTM 728.8m / Interest Expense TTM 64.3m)
EV/FCF = 26.98x (Enterprise Value 16.5b / FCF TTM 611.4m)
FCF Yield = 3.71% (FCF TTM 611.4m / Enterprise Value 16.5b)
FCF Margin = 17.32% (FCF TTM 611.4m / Revenue TTM 3.53b)
Net Margin = 14.38% (Net Income TTM 507.7m / Revenue TTM 3.53b)
Gross Margin = 44.42% ((Revenue TTM 3.53b - Cost of Revenue TTM 1.96b) / Revenue TTM)
Gross Margin QoQ = 44.89% (prev 43.05%)
Tobins Q-Ratio = 2.38 (Enterprise Value 16.5b / Total Assets 6.92b)
Interest Expense / Debt = 3.39% (Interest Expense 64.3m / Debt 1.90b)
Taxrate = 23.63% (37.1m / 157.0m)
NOPAT = 556.6m (EBIT 728.8m * (1 - 23.63%))
Current Ratio = 3.39 (Total Current Assets 1.72b / Total Current Liabilities 506.0m)
Debt / Equity = 0.47 (Debt 1.90b / totalStockholderEquity, last quarter 4.05b)
Debt / EBITDA = 1.40 (Net Debt 1.31b / EBITDA 939.1m)
Debt / FCF = 2.15 (Net Debt 1.31b / FCF TTM 611.4m)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.40% (Net Income 507.7m / Total Assets 6.92b)
RoE = 12.61% (Net Income TTM 507.7m / Total Stockholder Equity 4.03b)
RoCE = 12.36% (EBIT 728.8m / Capital Employed (Equity 4.03b + L.T.Debt 1.87b))
RoIC = 8.68% (NOPAT 556.6m / Invested Capital 6.41b)
WACC = 8.96% (E(15.2b)/V(17.1b) * Re(9.76%) + D(1.90b)/V(17.1b) * Rd(3.39%) * (1-Tc(0.24)))
Discount Rate = 9.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -72.55 | Cagr: -0.83%
[DCF] Terminal Value 74.57% ; FCFF base≈590.0m ; Y1≈639.5m ; Y5≈789.3m
[DCF] Fair Price = 129.9 (EV 10.9b - Net Debt 1.31b = Equity 9.62b / Shares 74.0m; r=8.96% [WACC]; 5y FCF grow 9.61% → 2.50% )
EPS Correlation: -50.87 | EPS CAGR: -1.75% | SUE: 3.48 | # QB: 5
Revenue Correlation: 67.28 | Revenue CAGR: 2.37% | SUE: 3.07 | # QB: 3
EPS current Quarter (2026-06-30): EPS=2.11 | Chg30d=+0.70% | Revisions=+47% | Analysts=13
EPS next Quarter (2026-09-30): EPS=2.19 | Chg30d=+0.51% | Revisions=+14% | Analysts=13
EPS current Year (2026-12-31): EPS=8.50 | Chg30d=+2.59% | Revisions=+75% | GrowthEPS=+6.9% | GrowthRev=+5.0%
EPS next Year (2027-12-31): EPS=9.23 | Chg30d=+2.74% | Revisions=+76% | GrowthEPS=+8.6% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +76%